Astrazeneca Plc $AZN Shares Purchased by Cibc World Market Inc.

Cibc World Market Inc. boosted its position in Astrazeneca Plc (NYSE:AZN) by 10.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 71,060 shares of the company’s stock after acquiring an additional 6,639 shares during the quarter. Cibc World Market Inc.’s holdings in Astrazeneca were worth $12,471,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. TD Asset Management Inc boosted its holdings in Astrazeneca by 2.1% in the fourth quarter. TD Asset Management Inc now owns 1,112,841 shares of the company’s stock valued at $195,304,000 after acquiring an additional 23,229 shares during the last quarter. Sivia Capital Partners LLC boosted its holdings in Astrazeneca by 16.6% in the fourth quarter. Sivia Capital Partners LLC now owns 7,996 shares of the company’s stock valued at $1,403,000 after acquiring an additional 1,137 shares during the last quarter. Lido Advisors LLC lifted its stake in shares of Astrazeneca by 1.5% during the fourth quarter. Lido Advisors LLC now owns 131,762 shares of the company’s stock worth $23,124,000 after purchasing an additional 1,985 shares in the last quarter. WCG Wealth Advisors LLC acquired a new position in shares of Astrazeneca during the fourth quarter worth about $6,297,000. Finally, GKV Capital Management Co. Inc. acquired a new position in shares of Astrazeneca during the fourth quarter worth about $1,580,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Astrazeneca Trading Up 2.3%

NYSE:AZN opened at $186.06 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71. The business’s 50-day simple moving average is $190.84 and its 200 day simple moving average is $184.91. The stock has a market cap of $288.57 billion, a price-to-earnings ratio of 27.94, a price-to-earnings-growth ratio of 1.56 and a beta of 0.25.

Astrazeneca (NYSE:AZN) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The business had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. As a group, sell-side analysts predict that Astrazeneca Plc will post 9.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. TD Cowen restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Weiss Ratings assumed coverage on Astrazeneca in a research note on Wednesday, March 11th. They set a “buy (b)” rating on the stock. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, May 13th. Finally, Barclays restated a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.